Philip L. Cyr, MPH

Pharma Insights

Economic Assessment of Novel Gene and Cellular Therapies: Beyond Traditional Modeling

04/17/2018

Various forms of decision health analytic modeling have been used for the last 3 decades to assess potential health economic impact of new therapies. As initial gene and cellular therapies come to market, debate is...

...

04/17/2018

Journal of Clinical Pathways

Viewpoint

Beyond the Current Standard of Care for Pediatric ADHD: A New Era of Digital Therapeutics

03/20/2019

Madison Preib , MPH;

Philip L. Cyr , MPH;

Joseph Honcz ;

Robert L. Findling , MBA, MD;

As the most common neurodevelopment disorder of childhood, attention-deficit/hyperactivity disorder (ADHD) places a significant burden on the US health care system.1-5 In today’s changing medical climate, there is growing pressure to improve...

As the most common...

03/20/2019

First Report Managed Care